Zacks Investment Research upgraded shares of QIAGEN NV (QGEN) from UNDERPERFORM to NEUTRAL on July 26, 2013, with a target price of $21.40.
Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on QIAGEN NV (QGEN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment